SNaPP Anaesthesia Study receives $2.9m grant from MRFF
Professor Kate Leslie AO FAHMS and co-investigators have received $2.9 million from the Medical Research Future Fund for the SNaPP study: Sugammadex, Neostigmine and Postoperative Pulmonary Complications.
This multicentre, comparative effectiveness trial will compare the incidence of death and new pulmonary complications up to hospital discharge (or postoperative day 7 if still in hospital) in patients aged 40 years and over having abdominal or thoracic surgery who are randomised to sugammadex (novel cyclodextrin reversal agent) or neostigmine for reversing neuromuscular blockade.
The patients will be followed up for lung complications (e.g. pneumonia) and quality of life. This information, along with health expenditure data, will be used to determine if sugammadex is cost-effective. The results of this study will have immediate benefits for patients and the healthcare system.